Released Nov 13, 2023, before the open
10-Q filed Nov 13, 2023, 44 days after period end · 0001140361-23-052742
Q3 2023 · 10-Q
Revenue$51.00K$51.00K — vs Q3 2022no prior Q2 2023 on file
Net Income-$5.59M-$5.59M N/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$1.03-$1.03 N/M vs Q3 2022N/M vs Q2 2023
Gross Profit-$69,000—
Operating Income-$5,505,000N/M
Operating Cash Flowderived-$5,826,000N/M
Free Cash Flowderived-$5,826,000N/M
Margins · derived
Gross margin-135.3%
Operating margin-10794.1%
Net margin-10962.7%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|
| Revenue | $51.00K | $0.00 | — | $1.48M |
| Net Income | -$5.59M | -$7.32M | -$85.99M | -$2.02M |
| EPS Diluted | -$1.03 | -$2.49 | -$34.03 | -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR